Pharma feed

N
Merck & Co., Inc.
聯合新聞網· 26 Sep 2020

TSMC cluster effect Merck plus code Taiwan.

[Translated] The clustering effect driven by TSMC (2330) has attracted the international semiconductor supply chain. Merck, the electronic materials and chemicals major, announced that it has chosen Kaohsiung as its investment capital for the next five years and is expected to increase its capacity by four adults over the next five years, when the production capacity of semiconductor materials in Taiwan will account for 20% of the Group's global share, double the current 10%.

  • Merck & Co., Inc.
  • Business Expansion
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Morningstar· 26 Sep 2020

GlaxoSmithKline Gets FDA Approval for Blood-Disorder Drug Nucala

By Kimberly Chin GlaxoSmithKline PLC has received the U.S. Food and Drug Administration's approval for the drug Nucala, which treats adult and pediatric patients with hypereosinophilic syndrome, a type of blood disorder. Nucala will become the first and only targeted biologic treatment to win approval for patients with eosinophil-driven disease in the U.S., the company said.

  • GlaxoSmithKline PLC
  • US Food and Drug Administration
  • New Offerings
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Better Life
Axis Bank· 26 Sep 2020

Axis Bank partners with Bayer’s Better Life Farming initiative in India

‘Better Life Farming’ is a global multi-stakeholder partnership to support smallholder farmers in developing economies to earn sustainable farm incomes In India, the partnership includes Bayer, IFC, Netafim, Yara Fertilisers, DeHaat, AgriBazaar, BigBasket, Tata Trusts and now Axis Bank Axis Bank will offer holistic and cost-effective financial solutions to smallholder farmers and rural farming communities.

  • Better Life
  • Axis Bank
  • Bayer AG
  • Partnerships and Alliances
  • Press Releases
  • Company Websites
N
GlaxoSmithKline PLC
FirstWord Pharma· 26 Sep 2020

GSK's Nucala becomes first biologic cleared in US for hypereosinophilic syndrome

GlaxoSmithKline said Friday that the FDA expanded approval for Nucala (mepolizumab) to include treatment of adult and paediatric patients aged 12 years and older with hypereosinophilic syndrome (HES).

  • GlaxoSmithKline PLC
  • US Food and Drug Administration
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
BW People· 26 Sep 2020

Trudeau announces vaccine pact as Canada surpasses 150,000 Covid cases

Toronto [Canada], September 26 (ANI/Sputnik): Canadian Prime Minister Justin Trudeau on Friday announced that his government has entered into an agreement with British pharmaceutical giant AstraZeneca to procure 20 million doses of its coronavirus vaccine. The number of COVID-19 cases in Canada has surpassed 150,000 with 9,250 deaths reported, the Canadian government data revealed on Friday.

  • AstraZeneca PLC
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Pharmafile· 26 Sep 2020

GSK confirms deal to supply 300 million COVID-19 vaccine doses to the EU

GlaxoSmithKline has confirmed a new COVID-19 vaccine supply deal to deliver 300 million doses of its candidate to the European Commission. On the condition that the vaccine secures regulatory approval, all European Union member states will be eligible to access the therapy.

  • GlaxoSmithKline PLC
  • Procurement and Sales
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Eisai Co Ltd
Pharmafile· 26 Sep 2020

Japan approves Gilead and Eisai's Jyseleca for rheumatoid arthritis

Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, Labour and Welfare as a treatment for rheumatoid arthritis (RA), it has emerged. The approval relates to patients for whom conventional therapies for the prevention of structural joint damage have not been effective.

  • Eisai Co Ltd
  • Gilead Sciences, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Novartis AG
Novartis AG· 26 Sep 2020

Senior Study Operations Manager, Clinical Sciences & Innovation

Job Description 7000 patients, 1200 clinical sites, 40 countries, 100+ clinical studies led by Novartis Clinical Sciences & Innovation (CS&I) last year. CS&I is a group of driven Clinical Scientists who plan and execute Novartis’ early phase global clinical trials.

  • Novartis AG
  • Clinical Trials
  • Job Postings
  • Company Websites
N
GlaxoSmithKline PLC
MarketScreener· 26 Sep 2020

GlaxoSmithKline : FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)

GlaxoSmithKline plc (GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-haematologic secondary cause.

  • GlaxoSmithKline PLC
  • US Food and Drug Administration
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Yahoo· 26 Sep 2020

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial

By Vishwadha Chander (Reuters) - A single dose of Johnson & Johnson's experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday.

  • Johnson & Johnson
  • Clinical Trials
  • News Articles
  • News and Other Websites
N
US Food and Drug Administration
BioPharma International· 25 Sep 2020

EMA and FDA Accept UCB’s Marketing Applications for Bimekizumab

A preview of this article is not available. Please click on the headline to read the complete article

  • US Food and Drug Administration
  • UCB SA
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Seeking Alpha· 25 Sep 2020

Merck (MRK) Presents at ESMO Virtual Congress - Slideshow (NYSE:MRK)

The following slide deck was published by Merck & Co., Inc. in conjunction with this event. Download PDF 1 22 Click to enlarge Notes:

  • Merck & Co., Inc.
  • Events
  • News Articles
  • News and Other Websites
N
Immunomedics Inc
GuruFocus· 25 Sep 2020

High Probability M&A Situation After Gilead Wins Bidding War

hen Gilead made its bid, it had been talking to Immunomedics about a deal for six months already. The parties apparently trusted each other because Gilead gained access to data that wasn't publicly available yet about Trodelvy.

  • Immunomedics Inc
  • Gilead Sciences, Inc.
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
Barrons· 25 Sep 2020

Why Covid-19 Vaccine Prices May Be Unexpectedly Low

Text size If the vaccines now in final clinical trials against Covid-19 prove effective and safe, there should be plenty to go around. Developers like Moderna (ticker: MRNA), Pfizer (PFE), BioNTech (BNTX), Johnson & Johnson (JNJ), Novavax (NVAX), and AstraZeneca (AZN) are preparing to make billions of doses.

  • AstraZeneca PLC
  • Clinical Trials
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
MSN Australia· 25 Sep 2020

Canada has signed deal for AstraZeneca vaccine candidate: PM

OTTAWA (Reuters) - Canada has signed a deal with Cambridge-based AstraZeneca PLC to buy up to 20 million doses of its COVID-19 vaccine candidate, Prime Minister Justin Trudeau said on Friday. Trudeau also told a news conference that Ottawa would invest C$440 million ($328 million) in the COVID-19 vaccine Global Access Facility, a global procurement mechanism designed to help deliver fair, equitable and timely access to vaccines.

  • AstraZeneca PLC
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Gilead Sciences, Inc.
QuoteMedia· 25 Sep 2020

Gilead and Galapagos\\\' filgotinib OK\\\'d in Europe for rheumatoid arthritis

Gilead and Galapagos' filgotinib OK'd in Europe for rheumatoid arthritis As expected, the European Commission approves Gilead Sciences' ([[GILD]] -0.5%) and collaboration partner Galapagos NV's ([[GLPG]] +3.2%) Jyseleca (filgotinib) for adults with moderate-to-severe rheumatoid arthritis

  • Galapagos NV
  • Gilead Sciences, Inc.
  • Partnerships and Alliances
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Gilead Sciences, Inc.
Seeking Alpha· 25 Sep 2020

Gilead and Galapagos' filgotinib OK'd in Europe for rheumatoid arthritis (NASDAQ:GILD)

As expected, the European Commission approves Gilead Sciences' (GILD -0.5% ) and collaboration partner Galapagos NV's (GLPG +3.2% ) Jyseleca (filgotinib) for adults with moderate-to-severe rheumatoid arthritis who have failed to respond to or are intolerant of one or more disease-modifying anti-rheumatic drugs.

  • Galapagos NV
  • Gilead Sciences, Inc.
  • Partnerships and Alliances
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Bristol-Myers Squibb Co
FirstWord Pharma· 25 Sep 2020

Opdivo and Yervoy Combination Therapy Approved in Japan to Expand Use for the Treatment of Microsatellite Instability High (MSI-High) Colorectal Cancer, and Opdivo for Additional Dosage and Administration in Monotherapy Dosing Regimen

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) and Bristol-Myers Squibb K.K. (Shinjuku, Tokyo; President, Jean-Christophe Barland; “BMSKK”) announced today that the companies have received approval for combination therapy of Opdivo®

  • Bristol-Myers Squibb Co
  • Ono Pharmaceutical Co Ltd
  • Business Expansion
  • News Articles
  • News and Other Websites
N
Gilead Sciences, Inc.
MarketScreener· 25 Sep 2020

Galapagos : European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca ® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs).

  • Galapagos NV
  • Gilead Sciences, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
MarketScreener· 25 Sep 2020

AstraZeneca : Canada has signed deal for AstraZeneca vaccine candidate - PM

OTTAWA, Sept 25 (Reuters) - Canada has signed a deal with Cambridge-based AstraZeneca to buy up to 20 million doses of its COVID-19 vaccine candidate, Prime Minister Justin Trudeau told reporters on Friday. The medication is among the leading candidates in the global race for a vaccine, now in late-stage trials in Britain, South Africa and elsewhere.

  • AstraZeneca PLC
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Gilead Sciences, Inc.
Express Pharma· 25 Sep 2020

Gilead gets approval for Jyseleca (filgotinib) in Japan for rheumatoid arthritis

Read Article Gilead Sciences announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead KK (Tokyo, Japan) regulatory approval of Jyseleca (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.

  • Gilead Sciences, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
  • Sanofi
  • Events
  • Social Updates
  • Twitter
N
Eisai Co Ltd
Gmpnews· 25 Sep 2020

Filgotinib Approved in Japan for Rheumatoid Arthritis

Gilead Sciences, Inc. and Eisai Co., Ltd. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.

  • Eisai Co Ltd
  • Gilead Sciences, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Bayer AG
Business Wire· 25 Sep 2020

Celmatix Achieves Second Milestone in Women’s Health Drug Discovery Alliance with Evotec

Celmatix Inc., the leading women’s health biotech focused uniquely on ovarian biology, today announced that the second milestone has been achieved in its five-year, multi-target alliance with Evotec. This milestone was triggered by Bayer and Evotec advancing a second drug program centered around a novel Celmatix-identified target from Evotec.

  • Bayer AG
  • Celmatix
  • Evotec AG
  • Partnerships and Alliances
  • Press Releases
  • Press Release Agencies
N
Axis Bank
The Economic Times· 25 Sep 2020

Axis Bank partners with Bayer's better life farming (BLF) initiative in India

JioMaruti SuzukiAir IndiaUS elections 2020Indian Airlines newsTelecom newsBanking newsFinance newsAuto News

  • Axis Bank
  • Bayer AG
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
1 2 3 4 5